We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

RGT Argent Biopharma Limited

-1.00 (-4.55%)
17 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Argent Biopharma Limited LSE:RGT London Ordinary Share AU0000326647 ORD NPV (DI)
  Price Change % Change Share Price Shares Traded Last Trade
  -1.00 -4.55% 21.00 3,407 08:00:00
Bid Price Offer Price High Price Low Price Open Price
20.00 22.00 21.00 21.00 21.00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Last Trade Time Trade Type Trade Size Trade Price Currency
16:23:46 O 2 20.00 GBX

Argent Biopharma (RGT) Latest News

Argent Biopharma (RGT) Discussions and Chat

Argent Biopharma (RGT) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type

Argent Biopharma (RGT) Top Chat Posts

Top Posts
Posted at 10/4/2024 16:49 by greedfear
All I have to do now is to find my share certificates. :(
Posted at 03/3/2016 08:20 by stenick
For anyone interest, from Rgt accounts.

Revenues from sales of ColostrininTM for the year to 31 December 2014 were £17,000 (2012 - £52,000). Administrative costs have come down from £179,000 last year to £95,000 in 2014. Overheads have again been kept to a minimum. It should also be noted that within this figure there are non-cash items of £80,000 compared with £155,000 in 2013. These charges represent depreciation of the filtration rig (£27,000), the amortisation of patents (£44,000) and the amortisation of goodwill (£9,000). As a result of these factors the loss for the period after tax amounted to £100,000 (2013 - £171,000).

On the 17th May 2012 the Company drew down the last £40,000 of the £240,000 loan facility available from Alexander David Investments PLC. With interest this has now accrued to a debt of £322,000 as at 31 December 2014 and interest continues to accrue. Technically this convertible loan could now be called upon after 14th February 2014. As previously stated this loan was taken over by Tiziana Life Sciences Plc after their acquisition of Alexander David Investments Plc (“ADI”). Discussions with Tiziana management have clarified that they do not intend to call in this loan but would convert this loan to RGTL shares at an appropriate time.

Sales are down from last year mainly as a result of an order not being placed by our US distributor during 2014, although an order was placed in early 2015. We are working with a new licensee in India to secure regulatory approval to distribute the product direct to consumers there. The application has been with the regulatory agency for some months and a decision is expected soon.

Our USA licensee Metagenics introduced a Colostrinin combination product (CerivaTM) via the 'professional' channel in summer 2014. Active ingredient for this launch stock was the main source of RGTL revenue in 2013. Detailed information is unavailable from Metagenics to ascertain how well the product is being received in the marketplace but the fact that they have recently suggested that no more material will be required during the remainder of 2015 or during the early part of 2016 suggests that the product is not selling as well as was hoped.

Having obtained regulatory approval to do so, Tagerr our distributor in Poland have now switched from distributing product made by Metagenics to tablets supplied by RGTL.These are being well received but obviously sales here are on a modest scale.

Cost saving initiatives continue. The Company runs from a virtual office. Both Directors and consultants remain unpaid (since December 2012) and will continue to defer their remuneration/fees until there is funding/finance available.

The Directors continue to explore various ways of financing and developing the company with its advisers and contacts in order to secure a viable future for the Company in the best interest of shareholders. This includes the outright sale of the Company to a buyer that has the resources to fully exploit the sales potential of Colostrinin. So far a serious potential buyer has not been identified.
Posted at 17/3/2015 18:32 by impala391
Time has stood still for Rgt.
Posted at 10/12/2014 19:14 by doorway
so whats going on here then are rgt still alive,and when this delisted did anyone get their new certs as mine was in a nominee account
Posted at 09/12/2014 07:37 by asmodeus
"cognisure unavailable, and not sure whether it will be again" (from site above, suggested by Share Shark)
Posted at 15/7/2011 10:10 by the_doctor
I'll repost this:

A quick report from the RGT update meeting.

8 shareholders, plus 2 from the company.
Tim did most of the talking, as expected.
He had clear visions and put them across well.
There have been issues, but they're doing what they can to get around them. I think we're in as good a pair of hands as we could hope with Tim really.
He's realistic about the challenges and is focused on the right areas.

Norman answered the financial questions without problem and again, appears realistic.

In short, 2011 has gone well.
I got the impression that orders so far already match those in 2010 (that wasnt said specifically) and more are anticipated.

They havent used up the first £150k portion of the loan yet
Cash burn rate of £20-25k per month.

On an approx 60% margin, if they've so far got £100k from 2011 trading...
I forget how much of the filtration unit/other expenses came out of the loan?
If £35k, then for operations, there'd be £115k from the loan

So, £225k in this year would mean they'd need to draw on the second part of the loan in Oct 2011.
From then, they'll have about 5 months worth of cash.

So, we have a window until approx end March 2012
But this will be extended with any further orders.
Which in turn, will buy more time for more orders to come in.

It looks tight to me, so orders over H2 2011 and H1 2012 are ESSENTIAL

They do have a lot of things bubbling away that should lift revenue AND importantly, also margins.
Producing their own RGT tablets increases the price RGT gets by about 50%.
That would translate into a nice lift in cash flows from ex-US sales.
Add to that, input from the recent/new distribution agreements signed...

My overall view is that if they can get to 2013, then they're home and dry, as more deals kick in and the margins improve.
The critical thing IMO is getting enough cash in to cover the 5-10 months running from end of the loans to sustainability...
That will require £100-250k
Or, orders of about £170-265k
Roughly translated, they have approaching a year to bring in as many orders as they did in the last 6 months, or the same as the whole of 2010.
That'll be facilitated by margin improvement and the launch of new formulations, but really depends on how long current stocks last before re-orders come in.... that's a bit of an unknown!
Speed is of the essence.

There isnt much scope for cost cutting, but I'd hope they'd cut back even further if they really had to, such as delaying/cutting down staff pay for a spell, putting them as creditors for what was owed until sustainable?
Posted at 18/2/2011 13:18 by fenseal3
The way i see it if someone bought today they would be buying into ADI and because it's a 3 day trade you would miss out on the free rgt shares, so that person would be buying into an investment company with 1.5m to spend with a MC of 1.5m if it drops to if they have something lined up who knows where the share price can be..ALO had no money but a couple of guys came on board and raised 2m they have signed 5 licences and have a holding of 10% in can buy in RGT/ADI now for 0.54 so if you think this will be higher in 12 monthe time then it's a good investment...if i am way off please post....ALO now has a MC of 8m
Posted at 18/2/2011 09:50 by lean5gb
....alby, these shares I can trade through Halifax are my RGT holdings, Not ADI

...RGT's share price is -28.6% at the mo.....RGT are trading today! ! !
Posted at 15/2/2011 12:27 by share_shark
A point to remember with regards to JP Jenkins.

At one time they operated as OFEX and if you had watched the action,on that market was very good with share price prices moving with the demand on there.

They were taken over and now operate as JP Jenkins but in essence,nothing has changed.

So before you all say goodbye,as RGT shareholders and hello as RGTnewco shareholders and not forgetting ADI shareholders,it may be worth considering your wishes on this BB,for selling your shares.

Ie. "Genises. I wish to sell 500000 shares,if anyone is interested at ??."

Then someone would notice( Maysun) and contact JPJenkins and agree such a sale.

Today is the last Board meeting of RGT's board of directors so lets hope a few of these well touted deals are forthcoming.

Good luck everyone and I hope that those of you who are going to attend RGTnewcos first shareholders meeting will take a camera with you and let the rest of us know,what the long,the short and small actually look like.I will look forward to that too.;-)))
Posted at 10/2/2011 12:07 by share_shark

Anyone holding RGT by close of business yesterday will be entitled to an additional 10% of their holding in RGT to subscribe for warrants( lets call them shares) in the new ADI and can sell,within two years at a price indicated.

So ,lets say you held 100000 shares in RGT yesterday, you will have 100000 shares in ADI PLUS a further 10000,in ADI, which you can sell or hold,once you have paid the o5p.within two years.

So three bites of the cherry as I have indicated earlier.

taking the 100000 shares as an example.

On the 18th Feb. you will have

100000 shares in RGTNewco LTD.

100000 ADI shares.

Plus you are entitled to 10000 shares in ADI(if you wish to exercise them)

Comprendi ?.
Argent Biopharma share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock